110 related articles for article (PubMed ID: 17074660)
41. (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.
Haerle SK; Strobel K; Hany TF; Sidler D; Stoeckli SJ
Head Neck; 2010 Mar; 32(3):319-25. PubMed ID: 19626642
[TBL] [Abstract][Full Text] [Related]
42. [[F-18]FDG imaging of head and neck tumors: comparison of hybrid PET, dedicated PET and CT].
Dresel S; Schwenzer K; Brinkbäumer K; Schmid R; Szeimies U; Pöpperl G; Hahn K
Nuklearmedizin; 2001 Oct; 40(5):172-8. PubMed ID: 11727630
[TBL] [Abstract][Full Text] [Related]
43. Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.
Nayak JV; Walvekar RR; Andrade RS; Daamen N; Lai SY; Argiris A; Smith RP; Heron DE; Ferris RL; Johnson JT; Branstetter BF
Laryngoscope; 2007 Dec; 117(12):2129-34. PubMed ID: 17921898
[TBL] [Abstract][Full Text] [Related]
44. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
Menda Y; Graham MM
Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
[TBL] [Abstract][Full Text] [Related]
45. Detection of occult bone metastases from head and neck squamous cell carcinoma: impact of positron emission tomography computed tomography with fluorodeoxyglucose F 18.
Basu D; Siegel BA; McDonald DJ; Nussenbaum B
Arch Otolaryngol Head Neck Surg; 2007 Aug; 133(8):801-5. PubMed ID: 17709620
[TBL] [Abstract][Full Text] [Related]
46. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology.
Yen TC; Chang JT; Ng SH; Chang YC; Chan SC; Wang HM; See LC; Chen TM; Kang CJ; Wu YF; Lin KJ; Liao CT
J Nucl Med; 2005 May; 46(5):775-81. PubMed ID: 15872350
[TBL] [Abstract][Full Text] [Related]
47. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective.
Dietl B; Marienhagen J; Kühnel T; Schreyer A; Kölbl O
Oral Oncol; 2008 May; 44(5):504-8. PubMed ID: 17826307
[TBL] [Abstract][Full Text] [Related]
48. Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient.
Lonneux M; Lawson G; Ide C; Bausart R; Remacle M; Pauwels S
Laryngoscope; 2000 Sep; 110(9):1493-7. PubMed ID: 10983949
[TBL] [Abstract][Full Text] [Related]
49. Delayed response assessment with FDG-PET-CT following (chemo) radiotherapy for locally advanced head and neck squamous cell carcinoma.
Prestwich RJ; Subesinghe M; Gilbert A; Chowdhury FU; Sen M; Scarsbrook AF
Clin Radiol; 2012 Oct; 67(10):966-75. PubMed ID: 22595082
[TBL] [Abstract][Full Text] [Related]
50. Pathology and FDG PET correlation of residual lymph nodes in head and neck cancer after radiation treatment.
Yao M; Luo P; Hoffman HT; Chang K; Graham MM; Menda Y; Tan H; Buatti JM
Am J Clin Oncol; 2007 Jun; 30(3):264-70. PubMed ID: 17551303
[TBL] [Abstract][Full Text] [Related]
51. Role of PET FDG in the management of head and neck squamous cell cancer.
Wong WL; Saunders M
Clin Oncol (R Coll Radiol); 1998; 10(6):361-6. PubMed ID: 9890536
[No Abstract] [Full Text] [Related]
52. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
Kostakoglu L; Goldsmith SJ
J Nucl Med; 2004 Jan; 45(1):56-68. PubMed ID: 14734674
[TBL] [Abstract][Full Text] [Related]
53. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy.
Miller FR; Karnad AB; Eng T; Hussey DH; Stan McGuff H; Otto RA
Head Neck; 2008 Jan; 30(1):28-34. PubMed ID: 17657782
[TBL] [Abstract][Full Text] [Related]
54. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
[TBL] [Abstract][Full Text] [Related]
55. [Contribution of 18-F-FDG PET for detection of head and neck carcinomas with an unknown primary tumor].
Fakhry N; Jacob T; Paris J; Barberet M; Mundler O; Giovanni A; Zanaret M
Ann Otolaryngol Chir Cervicofac; 2006 Feb; 123(1):17-25. PubMed ID: 16609665
[TBL] [Abstract][Full Text] [Related]
56. [Contribution of 18FDG PET/CT post treatment surveillance of head and neck squamous cell carcinoma].
Fakhry N; Barberet M; Paris J; Jacob T; Deveze A; Mundler O; Giovanni A; Zanaret M
Ann Otolaryngol Chir Cervicofac; 2006 Sep; 123(4):167-74. PubMed ID: 17088703
[TBL] [Abstract][Full Text] [Related]
57. F-18 FDG-PET as a routine surveillance tool for the detection of recurrent head and neck squamous cell carcinoma.
Lee JC; Kim JS; Lee JH; Nam SY; Choi SH; Lee SW; Kim SB; Kim SY
Oral Oncol; 2007 Aug; 43(7):686-92. PubMed ID: 17112775
[TBL] [Abstract][Full Text] [Related]
58. Workup of Suspected Chest Metastases on
Leto CJ; Sharbel D; Wang CW; Bone TM; Liebman RM; Byrd JK; Groves MW
Ear Nose Throat J; 2019 Mar; 98(3):158-164. PubMed ID: 30938238
[TBL] [Abstract][Full Text] [Related]
59. Do hardware artefacts influence the performance of head and neck PET scans in patients with oral cavity squamous cell cancer?
Goerres GW; Schmid DT; Eyrich GK
Dentomaxillofac Radiol; 2003 Nov; 32(6):365-71. PubMed ID: 15070838
[TBL] [Abstract][Full Text] [Related]
60. Head and neck cancers: post-therapy changes in muscles with FDG PET-CT.
Matthews R; Shrestha P; Franceschi D; Relan N; Kaloudis E
Clin Nucl Med; 2010 Jul; 35(7):494-8. PubMed ID: 20548140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
